

Date 02/03/2010

Consensus Rating*: 1.19 (Acc.)

Previous rating 0.77 (Acc.)

Stock price (in Euro) 15.74

High/Low (52 weeks) 16.46/11.51

Market cap (in Euro m) 3,043.1

ISIN NL0000240000

Reuters QGEN.DE

Bloomberg QIA:GR

Exchange XETRA

Sector Biotech

 Internet www.qiagen.com

Coverage 16

Qiagen


■ Summary

Qiagen Outlook given after Q3 2009 results:

FY 2009: New EPS adjusted guidance US\$ 0.88 - 0.90.

Qiagen will publish its FY 2009 results 9th February 2010.

EPS Estimates in US\$



Price targets in US\$

	Current	Previous	Change	Up-/Downside
Current Price	22.04			
Highest	25.86	25.20	2.6%	17.3%
Consensus	23.73	21.60	9.9%	7.7%
Median	23.80	21.28	11.8%	8.0%
Lowest	18.62	18.48	0.8%	-15.5%

YoY Change in Estimates

	FY 09E	FY 08A	Change
Sales	994.3	893.0	11.3%
EBIT clean	292.2	252.7	15.6%
EBIT	189.0	145.7	29.7%
EPS clean	0.91	0.80	13.3%
EPS	0.58	0.44	31.4%

clean = adjusted

* Consensus Rating (CR):

Classification:

 Buy: $1.50 \leq CR < 2.00$

 Accumulate: $0.50 \leq CR < 1.50$

 Hold: $-0.50 < CR < 0.50$

 Reduce: $-1.50 \leq CR < -0.50$


 Sell: $-2.00 \leq CR < -1.50$

Disclaimer: This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of relevant company. Such estimates and forecasts cannot be independently verified by reason of subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and

Consensus Valuation in US\$ m

	EPS clean	EBIT clean	P/E	EV/Sales	EV/EBIT	Div.Yield
2006	0.56	120.9	26.18	4.89	18.83	0.0%
2007	0.63	164.3	26.92	5.68	22.47	0.0%
2008	0.80	252.7	22.99	4.92	17.40	0.0%
2009E	0.91	292.2	23.06	4.95	16.84	0.0%
2010E	0.95	343.8	23.20	5.04	17.31	0.0%

FY 2010 Consensus Estimates



Quarterly Development in (US\$)

